Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxycobalamin response evaluation in methylmalonic acidemia
IRCT20211207053311N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of hydroxocobalamin in methylmalonic acidemia (MMA) and Methylmalonic acidemia with homocystinemia (MMAHC), sponsored by Mashhad University of Medical Sciences. Started Feb 2022; status: completed.
02
Drugs
hydroxocobalamin
03
Conditions
methylmalonic acidemia (MMA)Methylmalonic acidemia with homocystinemia (MMAHC)
Beyond the preview
Go deeper on IRCT20211207053311N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211207053311N1.